RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Newsoara BioPharma acquired China rights to a prostate/breast cancer treatment from Zenith Epigenetics, a Canadian company, in a $78 million agreement. ZEN-3694 is a BET inhibitor that is in US Phase II trials to treat metastatic castration-resistant prostate cancer and triple negative breast cancer. Newsoara agreed to pay $15 million in upfront and near-term development milestones plus another $63 million in sales milestones. It will also pay make 6% royalty payments. Source: China Biotoday
